Ken‐ichi Ogawara
- Pharmaceutical Science top 0.2%
- Advanced Drug Delivery Systems 36
- Drug Solubulity and Delivery Systems 23
- Advancements in Transdermal Drug Delivery 11
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery 32
- Pharmacology top 5%
- Oncology top 5%
- Drug Transport and Resistance Mechanisms 28
- Surfaces, Coatings and Films top 5%
-
- Nanoplatforms for cancer theranostics 13
-
- Protein Interaction Studies and Fluorescence Analysis 7
-
- Cancer, Hypoxia, and Metabolism 7
- Co-authors
- Kazutaka HigakiToshikiro KimuraKentaro FurumotoYoshinobu TakakuraMitsuru HashidaToshiya KaiTamer M. ShehataKeita Un
- Journals
- Biochemical and Biophysical Research Communications (4 papers)Journal of Controlled Release (16 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)
- Partner nations
- JapanNetherlandsEgypt
In The Last Decade
Ken‐ichi Ogawara
120 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 133
- Pharmaceutical Science 885
- Biomaterials 1.0k
- Pharmacology 163
- Oncology 483
- Surfaces, Coatings and Films 114
Countries citing papers authored by Ken‐ichi Ogawara
This map shows the geographic impact of Ken‐ichi Ogawara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken‐ichi Ogawara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken‐ichi Ogawara more than expected).
Fields of papers citing papers by Ken‐ichi Ogawara
This network shows the impact of papers produced by Ken‐ichi Ogawara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken‐ichi Ogawara. The network helps show where Ken‐ichi Ogawara may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ken‐ichi Ogawara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 16 | |
| 5 | 2023 | 10 | |
| 6 | 2022 | 13 | |
| 7 | 2022 | 3 | |
| 8 | 2017 | 9 | |
| 9 | 2013 | 5 | |
| 10 | 2011 | 122 | |
| 11 | 2008 | 13 | |
| 12 | 2007 | 58 | |
| 13 | 2007 | 21 | |
| 14 | 2006 | 16 | |
| 15 | 2004 | 21 | |
| 16 | 2004 | 161 | |
| 17 | 2003 | 18 | |
| 18 | 2001 | 4 | |
| 19 | 1999 | 111 | |
| 20 | 1998 | 23 |
About Ken‐ichi Ogawara
Ken‐ichi Ogawara is a scholar working on Pharmaceutical Science, Biomaterials and Pharmacology, having authored 123 papers that have together received 3.0k indexed citations. Recurring topics across this work include Advanced Drug Delivery Systems (36 papers), Nanoparticle-Based Drug Delivery (32 papers), Drug Transport and Resistance Mechanisms (28 papers), Drug Solubulity and Delivery Systems (23 papers), Nanoplatforms for cancer theranostics (13 papers), Advancements in Transdermal Drug Delivery (11 papers), Protein Interaction Studies and Fluorescence Analysis (7 papers) and Cancer, Hypoxia, and Metabolism (7 papers). The work is most often cited by research in Pharmaceutical Science (885 citations), Biomaterials (1.0k citations) and Pharmacology (163 citations). Ken‐ichi Ogawara has collaborated with scholars based in Japan, Netherlands and Egypt. Frequent co-authors include Kazutaka Higaki, Toshikiro Kimura, Toshikiro Kimura, Kentaro Furumoto, Yoshinobu Takakura, Mitsuru Hashida, Toshiya Kai, Tamer M. Shehata, Keita Un and Yusuke Kono. Their work appears in journals such as Biochemical and Biophysical Research Communications, Journal of Controlled Release and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.